Sulindac sulfide

Sulindac is a non-steroidal anti-inflammatory drug that has an extensive epidemiology documenting reduced human colorectal cancer. In mouse models, sulindac was found not only to inhibit the enzymatic activity of polyp-associated COX-2, but also to downregulate the expression of colonic COX-2 protein to control levels.[1] Sulindac sulfide is a metabolite of sulindac that has diverse activities.[2],[3] It inhibits both COX-1 and COX-2 (IC50s = 1.9 and 1.21 µM, respectively), whereas the parent compound, sulindac, is much less effective (IC50 = 58 µM for COX-2 and > 100 µM for COX-1).[4] Sulindac sulfide also inhibits aldose reductase (IC50 = 279 nM), blocking NADPH-dependent reduction of glucose to sorbitol, and reducing type 2 diabetic complications.[5] It increases the expression and activity of NAD(P)H quinone oxidoreductase [1].[6] Sulindac sulfide inhibits colorectal cancer growth both in vitro and in vivo.[7]

Reference:
[1]. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Research 56, 2556-2560 (1996).
[2]. Kitamura, S., and Tatsumi, K. In vitro metabolism of sulindac and sulindac sulfide: Enzymatic formation of sulfoxide and sulfone. Japanese Journal of Pharmacology 32(5), 833-838 (1982).
[3]. Brunell, D., Sagher, D., Kesaraju, S., et al. Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metabolism and Disposition 39(6), 1014-1021 (2011).
[4]. Warner, T.D., Giuliano, F., Vojnovic, I., et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Nat. Acad. Sci. USA 96(13), 7563-7568 (1999).
[5]. Zheng, X., Zhang, L., Zhai, J., et al. The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Letters 586(1), 55-59 (2012).
[6]. Kung, H.N., Weng, T.Y., Liu, Y.L., et al. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. PLoS One 9(2), 1-15 (2014).
[7]. Williams, C.S., Goldman, A.P., Sheng, H., et al. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1(2), 170-176 (1999).